



Management of Anticoagulants and Antiplatelet Agents

	Low Risk	High Risk
Enoxaparin (Clexane [®]) - prophylactic		Withhold 1 dose before
Enoxaparin (Clexane [®]) - therapeutic		Withhold 24h before
Heparin – subcut	Vo need to cease	Procedure 6h aft last dose
Heparin – IV		Withhold 4h before
Aspirin		Cease for 5 days (except uss breast bx)
Clopidogrel (Plavix [®])		Cease for 5 days
Dabigatran (Pradaxa®)	No need	CrCl > 50 – withhold 4 doses CrCl < 50 – withhold 8 doses
Rivaroxaban (Xarelto®)		CrCl > 50 – withhold 2 doses CrCl < 50 – withhold 3 doses
Apixaban (Eliquis®)		CrCl > 50 – withhold 4 doses CrCl < 50 – withhold 6 doses
Ticagrelor (Brillinta®)		Withhold for 5 days
Warfarin ®	See above INR recommendations	

Assessment of Patient Bleeding Risk

HAS-BLED Score (4 or higher = high risk of bleeding) Other risk factors for bleeding

- Prior bleeding within 3 months
- Prior bleeding within 5 months
 Prior bleeding with similar type of procedure
- Platelet abnormality
- Platelet abnormality
- INR above therapeutic range (Warfarin)
 Prior bleeding with bridging therapy
- Mechanical mitral heart valve
- Active cancer

HTN (SBP > 160)	1
Abnormal renal function (dialysis, renal transplant, Cr>200)	1
Abnormal LFT (cirrhosis or bili > 2xULN, AST or ALT >3xULN)	1
Prior stroke	1
History of major bleeding or predisposition to bleeding	1
Labile INR (time in therapeutic range <60%)	1
>65уо	1
Concomitant use of antiplatelet agent or NSAID	1
History of alcohol or drug use (>8 drinks per week)	1

*Chronic liver patients:

- paracentesis: No INR limit, require platelets >20 and fibrinogen >0.5 (as per hospital protocol)

- Low risk procedures: No INR limit, require platelets >20 and fibrinogen >1.0
- High risk procedures: INR < 2.5, require platelets >30 and fibrinogen >1.0

** Cardiac stent placed < 1yr: Continue aspirin, may with-hold second antiplatelet for 5 days before procedure, consult cardiology, vascular or internal medicine for management recommendations

Reference: SIR Consensus Guidelines for the Periprocedural Management of Thrombotic and Bleeding Risk in Patients Undergoing Percutaneous Image-Guided Interventions – Part II: Recommendations. J Vasc Interv Radiol 2019; 30:1168-1184